Press Release
Cross-Chain Money Market Governance Token, HARD, to be Co-Listed on BitMax.io
BitMax.io (BTMX.com), an industry-leading digital asset trading platform built by Wall Street quant trading veterans, has announced the primary co-listing of HARD Protocol’s HARD token (HARD) under the trading pair of HARD/USDT on November 6th at 10:00 a.m. EST.

HARD Protocol (previously Harvest.io) is a cross-chain money market that enables users to lend, borrow, and earn with their digital assets. HARD, the native governance token for the protocol, launched with the mainnet upgrade that took place on October 15th, 2020. The token can be used as collateral in the HARD Protocol supply and borrowing markets, as well as for voting on the management and evolution of the platform.
In contrast to other money markets, HARD opens DeFi to the larger cryptocurrency market, taking token holders beyond ETH access products like lending and borrowing. As an application built on multi-asset DeFi platform Kava, HARD is set to capitalize on the Kava-4 Mainnet upgrade which will introduce support for BTC, BUSD, XRP, and other digital assets. New digital assets will be also supported within the HARD Protocol money market alongside Kava native assets like KAVA, HARD, and USDX.
The HARD Protocol money market is the first project of its kind launched on the Kava blockchain. Kava gives the platform access to cross-chain assets, Chainlink oracles, and other key infrastructure. To support platform security and stability within this relatively new design paradigm, compared to Ethereum, HARD code is being audited by CERTIK, peer reviewed, and tested prior to listing.
“The primary co-listing of HARD on BitMax.io will be beneficial for both BitMax.io users and users of the Kava DeFi ecosystem,” said Shane Molidor, Global Head of Business Development at BitMax.io, “HARD offers investors a cross-blockchain money market to lend and borrow assets in a new way. This listing collaboration gives BitMax.io users exposure to HARD Protocol through the HARD token, and at the same time, allows HARD users to further invest in the platform’s governance.”
About BitMax.io
Launched in August 2018, BitMax.io is a leading digital asset trading platform with a broad range of financial products and services for both retail and institutional clients, with robust design ranging from innovative volatility products to margin trading, derivatives trading, staking products, and other investment solutions.
For more information and updates, please visit:
Website: https://bitmax.io/
Twitter: https://twitter.com/BitMax_Official
Telegram: https://t.me/BitMaxioEnglishOfficial
Medium: https://medium.com/bitmax-io
About HARD Protocol
HARD Protocol is the world’s first cross-chain money market that enables users to lend, borrow, and earn with their digital assets. Leveraging Kava’s blockchain security for DeFi products, the HARD Protocol will be expanded to support BTC, XRP, BUSD in HARD money markets along with native Kava assets like KAVA, HARD and USDX.
For more information and updates, please visit:
Website: https://harvest.io
Twitter: https://twitter.com/harvest_io
Telegram: https://t.me/harvest_io
Medium: https://medium.com/kava-labs/tagged/harvest
.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Neuralia TMS Breaks Down TMS Therapy Cost and Insurance Options
Australia, 20th Nov 2026 – Neuralia TMS, a specialist provider of transcranial magnetic stimulation (TMS) in Perth, Western Australia, has announced a plain breakdown of how funding works for patients considering TMS therapy, covering Medicare, referrals and private health insurance. According to the company, the explanation sets out which parts of a course are funded, which are not, and where patients are asked to confirm their circumstances before booking.

Neuralia TMS provides a non-invasive form of brain stimulation (link pending) in a specialised TMS suite, the company said. TMS uses an electromagnetic coil placed against the scalp to deliver magnetic pulses, and treatment is arranged as a course of sessions rather than a single visit. The company also offers transcranial direct current stimulation, known as tDCS, and pharmacogenetic testing, with clinics in Como, Kardinya and Armadale.
What the Announcement Means for Medicare Patients
Medicare is Australia’s public health insurance scheme, and some services attract a Medicare rebate when set criteria are met. According to Neuralia TMS, most patients on an initial Medicare-funded course pay $0 out of pocket for TMS at the clinic. The company states that Medicare covers up to 35 sessions in an initial course, and that a course is typically delivered five times a week over four to six weeks.
“Patients should be able to see what Medicare funds and what it does not before they book,” said Dr Shanek Wick, Medical Director of Neuralia TMS. “Eligibility depends on each person’s history, which is why the clinic asks patients to check their circumstances with the team.”
The company also states that a rebate applies only when every eligibility requirement is met. Previous TMS in any setting rules out the initial-course Medicare item, Neuralia TMS said, and an earlier course of treatment on its own does not show that a patient qualifies for a rebate. Patients are asked to contact the clinic about their circumstances, and the company refers them to a separate article on Medicare coverage for the full criteria.
How Referrals, Retreatment and Maintenance Work in Practice
A referral from a general practitioner or psychiatrist starts the Medicare eligibility process, although a referral does not establish eligibility by itself. Neuralia TMS says general practitioners can refer patients by Healthlink, fax or email using a standard referral letter, or through a secure online form. A team member then contacts the patient to book the first appointment. The team reviews the patient’s medical history and consults the referring practitioner before a treatment plan is prepared.

Separate arrangements apply to further treatment. Up to 15 retreatment sessions may be covered if needed, starting four months after the initial course, the company said, provided the criteria are met. Stand-alone maintenance TMS outside the initial and retreatment courses is not funded under the Medicare items, according to Neuralia TMS.
Patients who are not eligible for Medicare are directed to ask the clinic about their circumstances before booking. Enquiries from the Department of Veterans’ Affairs community are directed to a dedicated DVA cost resource or to the clinic team.
What Private Health Insurance May and May Not Cover
On private cover, the company says that private health insurance rarely covers the psychiatrist’s professional fees for TMS sessions delivered in a community setting. It advises patients to check with their insurer about those fees before starting treatment. Insurers set their own policy terms, and cover differs between funds and between levels of cover, so the company’s guidance is to confirm the details directly with the insurer rather than assume that a policy applies.

The statements in this release describe the arrangements as Neuralia TMS sets them out, and they do not amount to a promise of coverage for any individual patient. The company said that questions about funding can be put to the clinic by email before an appointment is made.
Looking Ahead
Neuralia TMS said the funding information is intended as a starting point, and that each patient’s position is confirmed individually once a referral has been received and the clinic has reviewed it.
“Clear funding information matters because the rules apply differently to each person, and the aim is for every patient to understand their position before treatment begins,” said Dr Wick. “Patients with questions are welcome to contact the clinic, and the team will go through their circumstances.”
About Neuralia TMS
Neuralia TMS is a Perth based provider of transcranial magnetic stimulation. The company also offers tDCS and pharmacogenetic testing, and its medical director is Dr Shanek Wick, a specialist psychiatrist.
For additional information about TMS therapy cost and related mental health service developments, contact Neuralia TMS by email at info@neuralia.com.au or call 1 6230 3996. The clinic is located at Unit 2A/125 Melville Parade, Marview House, Como, WA 6152.
Media Contact
Organization: Neuralia TMS (Como)
Contact Person: Dr Shanek Wick
Website: https://www.neuraliatms.com.au/
Email: Send Email
Contact Number: +6162303996
Address: Unit 2A/125 Melville Parade
Address 2: Marview House, Como WA 6152
Country: Australia
Release id: 50971
View source version on King Newswire:
Neuralia TMS Breaks Down TMS Therapy Cost and Insurance Options
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027
Amsterdam, Netherlands, 20th Nov 2026 – The global life sciences landscape is undergoing a structured realignment as precision medicine establishes itself as a foundational pillar of biopharmaceutical research and therapeutic development. Historically, pharmaceutical methodologies relied predominantly on broad-population models, applying standardized therapeutic interventions across heterogeneous patient cohorts. However, advances in high-throughput genomic sequencing, molecular profiling, and computational biology have fundamentally transformed this paradigm. Modern drug development strategies increasingly prioritize targeted mechanisms of action informed by distinct biological markers and individual genetic variations. As research institutions and commercial developers direct resources toward stratified medicine, the sector is witnessing a systemic shift toward therapeutic frameworks designed around biological specificity and diagnostic validation. This strategic transition reflects a broader recognition that clinical variance can be addressed through disciplined molecular characterization rather than generalized intervention models.

Within this evolving environment, revueltobio focuses its analytical and scientific efforts on the strategic intersection of molecular biology, pharmaceutical research, and computational methodologies. The identification of novel therapeutic targets now depends heavily on the capacity to process intricate biological datasets, decipher complex cellular signaling networks, and evaluate patient stratification criteria at earlier stages of development. By concentrating on the scientific concepts underpinning personalized therapeutic interventions, revuelto365 engages with the foundational questions that govern how targeted therapies move from initial conceptualization toward practical application in modern healthcare environments. In doing so, the organization prioritizes structural frameworks that align mechanistic research with translational potential across distinct disease profiles.
A critical dimension of this scientific transition is the growing reliance on advanced computational tools to enhance traditional laboratory workflows. The integration of artificial intelligence and machine learning within preclinical exploration has enabled research teams to analyze macromolecular structures, predict pharmacokinetic behaviors, and screen chemical libraries with higher analytical fidelity. In tracking these methodologies, revueltobio examines how computational biology can be systematically harmonized with empirical biological research to reduce timelines and resource expenditure in discovery programs. Through initiatives such as revuelto365, the organization assesses ongoing developments across analytical chemistry, biocomputing, and molecular modeling, tracking how these technologies contribute to more targeted, reliable scientific outcomes. The objective remains focused on evaluating computational models that can reliably reflect biological complexity without losing fidelity during empirical testing.
The implementation of precision healthcare frameworks also requires rigorous attention to diagnostic infrastructure and biomarker discovery. Therapeutic efficacy in stratified patient populations is intrinsically linked to the availability of robust diagnostic tools capable of identifying cellular anomalies, genetic predispositions, and disease-specific protein signatures. As biopharmaceutical organizations explore novel intervention pathways, understanding the interplay between genetic profiling and molecular mechanisms becomes paramount. revueltobio directs significant attention to these interdependencies, analyzing how continuous developments in molecular diagnostics and biomarker validation inform modern therapeutic design across diverse therapeutic areas, including oncology, immunology, and metabolic conditions. This analytical focus underscores the necessity of establishing clear correlations between measurable biological indicators and clinically relevant endpoints.
Furthermore, the translation of theoretical biology into functional therapeutic platforms presents significant methodological challenges that require rigorous evaluation. Preclinical validation pathways demand extensive characterization of pharmacokinetic and pharmacodynamic interactions, target engagement kinetics, and potential off-target effects. By evaluating the methodologies used to address these analytical hurdles, revueltobio highlights the critical importance of standardization across assay systems and experimental designs. Establishing reproducible experimental paradigms is essential to ensuring that therapeutic hypotheses are supported by robust biological evidence prior to downstream progression.
Looking toward the broader trajectory of healthcare and biotechnology, the sustained adoption of precision medicine depends on responsible innovation and a clear understanding of translational research requirements. The convergence of digital infrastructure, molecular biology, and pharmaceutical science presents complex scientific and operational questions that demand disciplined evaluation. revueltobio maintains a prospective orientation within the life sciences ecosystem, emphasizing scientific integrity, methodological rigor, and the careful examination of emerging technological frameworks that support the ongoing evolution of global healthcare. Through systematic observation of both computational developments and biological research paradigms, the entity continues to explore the principles shaping modern biopharmaceutical strategy.
What is revueltobio?
revueltobio is a biotechnology and life sciences entity focused on the exploration of pharmaceutical research, molecular biology, and technological methodologies that influence modern therapeutic discovery and precision medicine. The organization examines industry trajectories and research principles to better understand how scientific tools inform modern healthcare frameworks.
What areas of scientific research does revueltobio focus on?
revueltobio concentrates on several interconnected domains within the life sciences, including pharmaceutical discovery approaches, molecular biology, biomarker-driven precision medicine, and the application of advanced computational tools in biological research. Its work emphasizes the points of intersection between experimental biology and analytical infrastructure.
How does revueltobio approach precision medicine?
revueltobio views precision medicine as a crucial model for future healthcare delivery, focusing on how genomics, molecular biomarkers, and tailored diagnostic approaches enable more targeted and effective therapeutic strategies. This approach centers on moving away from generalized population treatment paradigms toward stratified biological models.
Does revueltobio incorporate computational biology and artificial intelligence into its framework?
revueltobio examines the utility of artificial intelligence, machine learning, and computational modeling as analytical tools designed to optimize biological data interpretation and support early-stage pharmaceutical discovery concepts. The focus is on evaluating how digital tools complement laboratory experimentation.
How does revueltobio view the role of biomarkers in modern drug development?
revueltobio recognizes biomarkers as vital components of modern translational medicine, essential for patient stratification, measuring biological responses, and validating targeted therapeutic mechanisms throughout the research process.
What is the primary mission guiding revueltobio?
The mission of revueltobio is to support scientific advancement by exploring innovative approaches in biotechnology and pharmaceutical research, grounded in scientific integrity and responsible technological integration. The organization seeks to clarify the concepts driving precision therapeutics.
How does revueltobio assess emerging biotechnology trends?
revueltobio evaluates emerging biotechnology trends through structured scientific analysis, monitoring technical developments in molecular diagnostics, computational life sciences, and therapeutic discovery frameworks to gauge their viability in translational research.
Is revueltobio focused on specific therapeutic categories?
revueltobio maintains a broad analytical perspective that spans multiple therapeutic fields where precision methodologies, molecular profiling, and targeted drug discovery frameworks are actively evolving, including oncology, immunology, and metabolic conditions.
Where can individuals learn more about revueltobio and its initiatives?
Information regarding revueltobio, its focus areas, and its perspectives on life sciences innovation is available through the organization’s official digital channels and publications, where it shares analytical insights into biotechnology developments.
About revueltobio
RevueltoBio – Advancing Biotechnology and Pharmaceutical Innovation
revuelto365 is a biotechnology and life sciences company focused on exploring the future of pharmaceutical research, drug discovery, and healthcare innovation. Through a science-driven approach, we aim to contribute to the advancement of modern medicine by bringing together emerging technologies, scientific knowledge, and innovative research concepts.
Our areas of interest span pharmaceutical development, molecular biology, biotechnology, precision medicine, and next-generation therapeutic technologies. We recognize the growing importance of artificial intelligence, computational biology, and advanced analytical methods in shaping the future of drug discovery and pharmaceutical research.
Our Mission
Our mission is to support scientific progress by exploring innovative approaches to pharmaceutical research and biotechnology. We believe that responsible innovation, scientific integrity, and technological advancement are essential to addressing the evolving challenges of global healthcare.
Our Vision
Our vision is a future in which biotechnology and pharmaceutical innovation contribute to more precise, efficient, and accessible healthcare solutions worldwide.
Our Areas of Focus
– Pharmaceutical Research: Exploring scientific approaches and emerging technologies relevant to modern drug discovery and development. – Biotechnology Innovation: Examining advances in molecular biology, biological sciences, and next-generation therapeutic technologies. – Precision Medicine: Supporting awareness of personalized healthcare approaches informed by genetics, biomarkers, and advanced diagnostics. – Artificial Intelligence in Healthcare: Exploring the potential of AI, machine learning, and computational technologies in pharmaceutical research. – Life Sciences: Following scientific developments that may shape the future of medicine, biotechnology, and global healthcare.
Looking Toward the Future
As biotechnology continues to evolve, RevueltoBio is committed to a forward-looking perspective that emphasizes scientific knowledge, responsible innovation, and the potential of emerging technologies.
We believe the future of healthcare will be shaped by the convergence of biological sciences, advanced computing, and pharmaceutical innovation.
RevueltoBio — Exploring Science. Advancing Possibilities.
Media Contact
Organization: revueltobio
Contact Person: Daniel Vermeer
Website: https://revueltobio.com
Email: Send Email
Address: 123 Science Park
City: Amsterdam
Country: Netherlands
Release id: 50976
View source version on King Newswire:
Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
NiobiumX Mining Inc. (OTCQB: NIOXF): Niobium Is Behind US Missiles and Next-Generation AI Chips. The US Imports All of It.
Toronto, Canada, November 20th, 2026, FinanceWire
- Alphabet, Amazon, Microsoft and Meta plan more than $700 billion of 2026 capital spending, Sherwood News reported; SIPRI put 2025 world military spending at a record $2.887 trillion.
- Niobium goes into jet engines and rockets, the Royal Society of Chemistry says. The US has not mined it since 1959, according to the USGS.
- NiobiumX Mining Inc. (OTC: NIOXF), an early-stage explorer with no resource estimate, holds claims in Quebec beside Niobec, North America’s only producing niobium mine.
Alphabet, Amazon, Microsoft and Meta plan to spend more than $700 billion on capital expenditures in 2026, Sherwood News reported. Amazon alone expects about $220 billion, CEO Andy Jassy said in July.
Military budgets set their own record. World military spending reached $2.887 trillion in 2025, the 11th consecutive annual rise, according to SIPRI.
Those are the budgets behind two familiar groups of shares, defense stocks and AI infrastructure stocks. One metal appears on both sides of the ledger.
NiobiumX (OTC: NIOXF) holds ground beside the only producing niobium mine in North America. Proximity to that mine is not necessarily indicative of mineralization on NiobiumX’s property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The company is an early-stage explorer, and it holds no interest in that mine, Niobec.
Niobium has established defense applications and emerging applications in AI computing. It is one of the critical minerals behind America’s weapons and the next generation of AI computing, used in the jet engines, rocket motors and missiles of the US military and in the superconducting circuits being developed to cut AI’s power and heat. The US produces none of it: according to the US Geological Survey, America has not mined niobium since 1959 and imports all of it.
Defense stocks and the niobium alloy inside jet and rocket engines
On the defense side, niobium goes into heat-resistant alloys. Inconel 718, a superalloy used in aircraft and land-based gas turbine engines and liquid-fuelled rockets, contains 4.75% to 5.50% niobium plus tantalum, according to maker Special Metals. CSIS calls niobium “indispensable for critical components in hypersonic vehicles.”
Separately, the Congressional Budget Office estimated in September that the US had used between one-half and two-thirds of its stock of certain interceptors, among them Patriot, THAAD, SM-3 and SM-6. Rebuilding could take at least five years, Defense News reported on the CBO estimate. These figures do not indicate the niobium content of these interceptors.
In the US, steels take about 77% of niobium use and superalloys about 23%, the USGS says.
AI stocks and the niobium compound in next-generation chips
Electricity demand from data centers rose 17% in 2025, against 3% growth in global demand, the International Energy Agency says. The agency projects data-center electricity use will roughly double, from 485 terawatt-hours in 2025 to 950 in 2030.
On September 7, 2026, the research institute imec reported circuits built on niobium titanium nitride using standard 300 mm wafers. imec says superconducting technology has the potential to outperform state-of-the-art CMOS by 100 times in energy efficiency. That figure is imec’s estimate, and superconducting computing remains at the research and early development stage. Its program targets “foundries, hyperscalers and system companies.”
Which country is the largest producer of niobium?
Brazil. It accounts for about 93% of global production and Canada about 5%, according to the US Geological Survey’s 2026 niobium data. US imports are worth about $525 million a year.
Ownership matters for anyone researching niobium stocks. CBMM, which CSIS says controls three-quarters of Brazil’s output, is privately held. Niobec in Quebec, the only primary niobium producer outside Brazil according to its owner, has been private since 2015. A Nebraska project is developing what would be the only US niobium mine, but it is not producing, the USGS says.
NIOXF: the Quebec claims beside North America’s only niobium mine
NiobiumX’s Shipshaw Property comprises 48 mineral claims totalling about 2,686 hectares in the Saguenay region of Quebec, the company says. It also says its nearest claim boundary lies less than 2 km from Niobec’s mining-lease boundary. Proximity to Niobec is not necessarily indicative of mineralization on the Shipshaw Property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone that Géologie Québec selected for characterization in a 2024 metallogenic bulletin, according to the company. Selection for characterization does not establish the presence of niobium mineralization.
Shipshaw has no resource estimate, and proximity to a producing mine does not mean similar mineralization. Its next steps are set out in the company’s October exploration update, and company information is at niobiumx.com.
About Us
NiobiumX Mining Inc. is a Canadian mineral exploration company focused on niobium and rare earth elements. The Company’s principal asset is the Shipshaw Property, a package of 48 mineral claims totalling approximately 2,686 hectares in the Saguenay region of Québec, situated within the Saguenay Graben of the Grenville Geological Province. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone selected for characterization by Géologie Québec in metallogenic bulletin BM 2024-02. The Company has no current mineral resource or reserve estimate on the property. Niobium is designated a critical mineral by Canada, the United States, the European Union and Australia.
Key facts
- Alphabet, Amazon, Microsoft and Meta 2026 capital spending plans: more than $700 billion (Sherwood News)
- Amazon’s expected 2026 capital spending: about $220 billion (CEO Andy Jassy)
- World military spending, 2025: a record $2.887 trillion (SIPRI)
- US niobium imports: about $525 million a year (USGS)
- US niobium end use: steels about 77%, superalloys about 23% (USGS)
- Shipshaw Property: 48 claims, about 2,686 hectares (NiobiumX)
Campaign Disclosure
Click here to read the full NiobiumX Mining Inc. campaign disclosure, including details regarding the publisher’s compensation, conflicts of interest, and other important disclaimers relating to these materials.
Contact
President
Kirby Renton
NiobiumX Mining Inc.
contact@niobiumx.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release2 days ago
Comment, Analysis on Google Gemini for Healthcare by Industry Analyst Jeff Kagan
-
Press Release3 days ago
OiLChef Wins Restaurant Solution of the Year Award at 2026 Restaurant & Takeaway Innovation Expo
-
Press Release4 days ago
Metrika Develops Blockchain Network Dashboard Prototype Based on GL1 Market Infrastructure Toolkit
-
Press Release1 week ago
Red Banyan CEO Evan Nierman Leads High-Stakes Communications Workshop at NASDDDS Annual Conference
-
Press Release6 days ago
IntelliVIX Wins Two CES 2027 Innovation Awards, Showcasing Global Competitiveness in Safety AI
-
Press Release6 days ago
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
Press Release7 hours ago
Airwheel Unveils Smart Cabin Luxury Hand 20 inch Carry On Airport Boarding Ai Wheel Suitcase for Every Kind of Traveler Luggage
-
Press Release6 days ago
Eurotrace net Unveils New Blockchain Intelligence Research Initiative
